(Q46328501)

English

Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy

scientific article published on 7 October 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18839220

Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18839220

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

(3aS)-palonosetron

1 reference

based on heuristic

inferred from title

author name string

Maurizio Musso

1

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18839220

Renato Scalone

2

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18839220

Vincenza Bonanno

3

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18839220

Alessandra Crescimanno

4

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18839220

Vita Polizzi

5

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18839220

Ferdinando Porretto

6

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18839220

Tania Perrone

8

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18839220

Carlo Bianchini

7

0 references

publication date

7 October 2008

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18839220

Supportive Care in Cancer

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18839220

17

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18839220

2

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18839220

205-209

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18839220

https://scigraph.springernature.com/pub.10.1007/s00520-008-0510-5

0 references

Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists

1 reference

https://api.crossref.org/works/10.1007%2FS00520-008-0510-5

21 January 2018

The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro

1 reference

https://api.crossref.org/works/10.1007%2FS00520-008-0510-5

21 January 2018

Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron

1 reference

https://pubmed.ncbi.nlm.nih.gov/18839220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antiemetic efficacy of granisetron plus dexamethasone in bone marrow transplant patients receiving chemotherapy and total body irradiation

1 reference

https://pubmed.ncbi.nlm.nih.gov/18839220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acute emesis: moderately emetogenic chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18839220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Control of delayed nausea and vomiting with granisetron plus dexamethasone or dexamethasone alone in patients receiving highly emetogenic chemotherapy: a double-blind, placebo-controlled, comparative study

1 reference

https://pubmed.ncbi.nlm.nih.gov/18839220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevention of emesis from multiple-day and high-dose chemotherapy regimens

1 reference

https://pubmed.ncbi.nlm.nih.gov/18839220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18839220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18839220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18839220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/18839220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18839220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prospective evaluation of antiemetic outcome following high-dose chemotherapy with hematopoietic stem cell support

1 reference

https://pubmed.ncbi.nlm.nih.gov/18839220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis

1 reference

https://pubmed.ncbi.nlm.nih.gov/18839220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18839220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron

1 reference

https://pubmed.ncbi.nlm.nih.gov/18839220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18839220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18839220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ondansetron versus ondansetron, dexamethasone, and chlorpromazine in the prevention of nausea and vomiting associated with multiple-day cisplatin chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18839220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference. The Granisetron Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/18839220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications

1 reference

https://pubmed.ncbi.nlm.nih.gov/18839220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Proposal for classifying the acute emetogenicity of cancer chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18839220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18839220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Delayed emesis: moderately emetogenic chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18839220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A double-blind, randomised, parallel study comparing intravenous dolasetron plus dexamethasone and intravenous dolasetron alone for the management of fractionated cisplatin-related nausea and vomiting

1 reference

https://pubmed.ncbi.nlm.nih.gov/18839220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antiemetic therapy for high-dose chemotherapy with transplantation: report of a retrospective analysis of a 5-HT(3) regimen and literature review

1 reference

https://pubmed.ncbi.nlm.nih.gov/18839220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18839220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Granisetron plus dexamethasone versus granisetron alone in the prevention of vomiting induced by conditioning for stem cell transplantation: a prospective randomized study

1 reference

https://pubmed.ncbi.nlm.nih.gov/18839220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New treatment options for chemotherapy-induced nausea and vomiting

1 reference

https://pubmed.ncbi.nlm.nih.gov/18839220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18839220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Granisetron vs ondansetron for prevention of nausea and vomiting in hematopoietic stem cell transplant patients: results of a prospective, double-blind, randomized trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18839220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00520-008-0510-5

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18839220

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18839220

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46328501&oldid=2105435640"